Table 6 Pharmacological Treatment used in all JIA subtypes
From: Juvenile idiopathic arthritis in Jordan: single center experience
Subtype | Oligoarticular | Polyarticular | Systemic arthritis | Psoriatic arthritis | Enthesitis Related arthritis | Total (%) |
|---|---|---|---|---|---|---|
Drug | ||||||
NSAIDs | 102 | 9 | 34 | 15 | 14 | 174 (82.8%) |
steroid | 110 | 17 | 36 | 15 | 8 | 191 (91%) |
 oral | 84 | 17 | 36 | 15 | 8 | 160 (76.1) |
 IA | 96 | 8 | 26 | 4 | 2 | 136 (64.7%) |
 IV | 6 | 8 | 17 | 2 | 0 | 33 (15.7%) |
MTX | 87 | 26 | 32 | 18 | 8 | 171 (81.4%) |
HCQ | 4 | 0 | 0 | 0 | 0 | 4 (1.9%) |
MMF | 1 | 0 | 0 | 0 | 0 | 1 (0.5%) |
leflunomide | 4 | 0 | 0 | 0 | 2 | 6 (2.8%) |
Cyclosporine | 0 | 0 | 5 | 2 | 0 | 7 (3.3%) |
Sulfasalazine | 2 | 0 | 0 | 0 | 0 | 2 (0.95%) |
Infliximab | 12 | 5 | 6 | 3 | 4 | 30 (14.2%) |
Etanercept | 14 | 0 | 2 | 7 | 2 | 25 (12%) |
Adalimumab | 12 | 0 | 2 | 1 | 0 | 15 (7.1%) |
Tocilizumab | 2 | 0 | 15 | 0 | 0 | 17 (8%) |
Anakinra | 0 | 0 | 1 | 0 | 0 | 1 (0.5%) |
Rituximab | 0 | 2 | 5 | 1 | 0 | 8 (3.8%) |
Golimumab | 2 | 2 | 0 | 0 | 0 | 4 (1.9%) |
Secukinumab | 0 | 0 | 0 | 3 | 2 | 5 (2.3%) |